How Does GLP-1 Affect Diabetes?
Therapeutic potential of GLP-1 in type 2 diabetes mellitus | Download Table
GLP-1R and Diabetes
Neue Diabetemedikamente Typ-2-Diabetes - diabetes-news : diabetes-news
Medikamente gegen Typ-2-Diabetes: GLP-1-Analoga | Apotheken Umschau
GLP-1 receptor agonist for type 2 diabetes - Clinical Advisor
Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes
Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus | SpringerLink
GLP-1: Actions on Beta-cell Mass and Function
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial - The Lancet
JCI Insight - Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes
Kidney and Dialysis | Free Full-Text | GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors | The Review of Diabetic Studies
GLP-1 receptor agonists used to treat type 2 diabetes* | Download Table
GLP-1 receptor agonists in type 2 diabetes: An underused asset? Updated January 2021 - DiabetesontheNet
Oral GLP1 Gene Delivery by an Antibody-Guided Nanomaterial to Treat Type 2 Diabetes Mellitus | ACS Applied Materials & Interfaces
Treatment of type 2 diabetes with incretin-based therapies - The Lancet
Emerging Role of Dual GLP-1 and GIP Receptor Agonists | DMSO
Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus
GLP-1 gene delivery for the treatment of type 2 diabetes: Molecular Therapy
GLP-1 Receptor Agonists for Type 2 Diabetes: Incorporating the Latest Treatment Options Into Individualized Care
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology
Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia | Science Advances
2 Medikamentöse Therapie des Glukosestoffwechsels — Leitlinien.de
Glucagon-like Peptide-1 Plasmid Construction and Delivery for the Treatment of Type 2 Diabetes: Molecular Therapy
